

Neurourology and urodynamics.(IM)
v. 20, no. 4 (2001)
General Collection
W1 NE3495M
2001-08-06 07:19:19

NEUROUROLOGY AND URODYNAMICS

Volume 20, Number 4, 2001



PROCEEDINGS OF THE
INTERNATIONAL CONTINENCE SOCIETY

31ST ANNUAL MEETING

SEOUL, KOREA

18-21 SEPTEMBER 2001

 WILEY-LISS

This journal is online
erscience[®]
terscience.wiley.com

DOCKET
ALARM

Find authenticated court documents without watermarks at docketalarm.com.

NEUROUROLOGY AND URODYNAMICS

EDITOR-IN-CHIEF

Jerry G. Blaivas, M.D.

Clinical Professor of Urology

Cornell University Medical School

Address journal correspondence to:

400 East 56th Street · New York, NY 10022, USA

DEPUTY EDITORS

Paul Abrams, M.D., F.R.C.S.

Bristol Urological Institute

Southmead Hospital

Bristol, UK

Alan J. Wein, M.D.

Professor and Chairman

Division of Urology

University of Pennsylvania

Medical Center

Philadelphia, PA, USA

The Official Journal of

**International Continence
Society**

**Society for Urodynamics
& Female Urology**


© 2001 Wiley-Liss, Inc. All rights reserved. No part of this publication may be reproduced in any form or by any means, except as permitted under section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the publisher, or authorization through the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, (508) 750-8400, fax (508) 750-4470. Requests to the publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc.

Neurourology and Urodynamics (Print ISSN 0733-2467; Online ISSN 1520-6777 at Wiley InterScience, www.interscience.wiley.com) is published six times a year by Wiley-Liss, Inc., a division of John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012. **Send subscription inquiries to:** John Wiley & Sons, Inc., Subscription Department, 9th floor, 605 Third Avenue, New York, NY 10158 (212) 850-6543. **Offprint sales and inquiries** should be directed to the Customer Service Department, John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012, (212) 850-6645. **Subscription price:** Volume 20, 2001, six issues: \$1195 in the U.S., \$1255 in Canada and Mexico, \$1306 outside North America. **Special Personal Subscription Rate:** For 2001, \$195 within North America, \$231 outside North America. Subscriptions at the personal rate must be made by personal check, credit card, bank draft or money order. All subscriptions outside North America will be sent by air. Payment must be made in U.S. dollars drawn on a U.S. bank. **Special "Physician in Training" rate:** Volume 20, 2001 \$98.00 in the U.S. To receive the "Physician in Training" rate, orders should be accompanied by the signature of the residency coordinator on institutional letterhead. **Members of the International Continence Society and Society for Urodynamics & Female Urology receive the journal as part of their dues.** **Change of address:** Please forward to the subscriptions address listed above 6 weeks prior to move; enclose present mailing label with change of address. **Claims** for undelivered copies will be accepted only after the following issue has been received. Please enclose a copy of the mailing label or cite your subscriber reference number in order to expedite handling. Missing copies will be supplied when losses have been sustained in transit and where reserve stock permits. If claims are not resolved satisfactorily, please write to: Caroline Rothaug, Subscription Fulfillment and Sales, John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158. **Cancellations:** Subscription cancellations will not be accepted after the first issue has been mailed. **Postmaster:** Send address changes to **Neurourology and Urodynamics**, Subscription Systems and Distribution, John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158. **Indexed by:** Index Medicus/MEDLINE · BIOSIS Data Base · Chemical Abstracts · Current Contents/Clinical Medicine · Excerpta Medica · ISI-Russian Academy · Scisearch. **Printed in the United States of America.**
Copyright © 2001 Wiley-Liss, Inc.

This journal is printed on acid-free paper.

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.



International Continence Society

31st Annual Meeting

Seoul, Korea
18th – 21st September 2001

Chair – Prof Kwang Myung Kim

Conclusions:

The bladder selectivity of tolterodine IR when compared to oxybutynin IR extends to the once-daily formulation of these products. Tolterodine once-daily has selectivity for the bladder versus salivation while Ditropan XL has an overall greater effect on salivation than on the bladder.

References:

- 1) Nilvebrant L, et al. Eur J Pharmacol. 1997; 327: 195-207.
- 2) Appell RA, Urology 1997; 50 (6A Suppl.): 90-96
- 3) Abrams P, et al. Br J Urol 1998; 81: 801-810
- 4) Drutz H, et al. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10: 283-289

Supported by Pharmacia Corporation

24

Authors: (1) W. Stewart (2) R. Herzog (3) A. Wein (4) P. Abrams (5) C. Payne (6) R. Corey (7) T. Hunt (8) NOBLE Program Research Team

Institution: (1) Innovation Health Solutions,(2) University of Michigan,(3) University of Pennsylvania (4) Bristol Urological Institute,(5) Stanford University,(6) Philadelphia College of Pharmacy (6), (7) Pharmacia Corporation

Title: PREVALENCE AND IMPACT OF OVERACTIVE BLADDER IN THE US: RESULTS FROM THE NOBLE PROGRAM

Aim of Study:

Overactive bladder (OAB) is a common problem affecting millions of people in the US. There are no reliable data as to the prevalence and burden of illness of this condition. Although OAB is an inclusive term describing the population of patients suffering from urinary urgency and frequency with or without urge incontinence, there are no data at all as to the clinical significance and impact of OAB without incontinence (OAB Dry) as compared with individuals with incontinence (OAB Wet). In addition, although OAB is easily understood clinically, there is no agreed objective definition for research use. The National Overactive BLadder Evaluation (NOBLE) Program was conducted to provide a clinically valid research definition of OAB, then to establish estimates of its overall prevalence, the individual burden of illness, and to explore differences between the OAB Wet and OAB Dry populations.

Methods:

A computer assisted telephone interview (CATI) was developed to estimate variation in prevalence of OAB by demographic and other factors. The CATI was assessed for reliability and clinical validity. Clinical validity of the CATI was assessed in a Baltimore-based community sample, where the CATI diagnosis was compared to a clinician's diagnosis. The sensitivity and specificity of the CATI for OAB were 61% and 91%, respectively. As previously reported, the CATI was proven reliable [1]. The validated US national telephone survey used a quota sampling method to select 5,204 English-speaking adults (≥ 18 years of age) representative of the US non-institutionalized population with regard to gender, age, and geographic region. OAB Dry was defined ≥ 4 episodes of urgency in the preceding 4 weeks, and either frequency more than 8 voids/day or the use of one or more coping behaviors to control bladder function. OAB Wet included the same criteria as OAB Dry plus ≥ 3 episodes of urinary incontinence in the past 4 weeks that could not be explained by stress symptoms. During the CATI, participants were asked questions about bladder symptoms and coping behaviors. To assess illness impact, OAB cases and matched controls from the national survey completed self-administered questionnaires on quality of life (SF-36), quality of sleep (MOS Sleep), and depression status (CES-D questionnaire).

Results:

The overall prevalence of OAB was 16.9% in women and 16.0% in men, increasing with age. The overall prevalence of OAB Dry and OAB Wet was 7.6% and 9.3% in women, respectively, and 13.6% and 2.6%, respectively, in men. Quality of life and symptom data were collected on 215 OAB Dry and 164 OAB Wet cases and 512 matched controls. After adjusting for differences in comorbid illnesses (ie, congestive heart failure, diabetes, selected neurological diseases, and cancer) and other demographic factors, OAB Wet and Dry cases in women and men had clinically and significantly lower quality of life (SF-36 subscores), lower depression status (higher CES-D depression scores), and poorer quality of sleep (higher MOS sleep scores). For many of the measures, OAB Dry was similar to OAB Wet (Table).

Mean scores (SE) in measures of QoL (SF-36, depression, and sleep) between OAB cases and age-matched controls				
Outcome	Gender	Controls	OAB Dry	OAB Wet
SF-36 --Physical Health Summary Score	W	49.4 (0.6)	45.3 (1.4)**	39.3 (1.2)***
	M	49.8 (0.7)	46.3 (1.0)**	41.3 (1.9)***
SF-36 --Mental Health Summary Score	W	49.7 (0.6)	45.1 (1.4)**	46.8 (1.0)*
	M	53.6 (0.6)	49.3 (0.9)***	47.7 (1.9)***
CES-D (overall score)	W	11.7 (0.6)	17.3 (1.6)***	17.1 (1.1)***
	M	7.4 (0.6)	13.0 (0.9)***	16.7 (1.8)***
MOS Sleep (mean)	W	26.4 (0.9)	35.4 (2.4)***	38.6 (1.8)***
	M	20.1 (1.1)	27.5 (1.5)***	32.9 (2.8)***

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.